FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135087888> ?p ?o ?g. }

• W2135087888 endingPage "1498" @default.
• W2135087888 startingPage "1493" @default.
• W2135087888 abstract "Within this phase II EORTC trial, we have investigated the safety and efficacy of pentostatin in lymphoid malignancies. We have previously reported the results in T- and B-cell prolymphocytic leukemia, B-cell chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia. This report focuses on the outcome in T-cell malignancies: T-CLL, Sézary syndrome (Sézary), mycosis fungoides (MF) and T-zone lymphoma (TZL).Of the 92 patients with these diagnoses enrolled, 76 were evaluable for response and toxicity, i.e., 25 of 28 with T-CLL, 21 of 26 with Sézary, 22 of 26 with MF, and 8 of 12 with TZL. All patients had progressive and advanced disease. Pentostatin was administered at a dosage of 4 mg/m2 every week for the first 3 weeks, then 4 mg/m2 every 14 days for another 6 weeks, followed by maintenance therapy of 4 mg/m2 monthly for a maximum of 6 months.Response rates (complete and partial responses) in patients with Sézary (n = 22) or MF (n = 21) were 33% and 23%, respectively, and in patients with T-CLL (n = 21) or TZL (n = 8) 8% and 25%, respectively. Sixteen (21%) patients died during the first ten weeks of treatment: twelve of progressive disease, two of infectious complications with progressive disease, one of myocard infarction and one of renal failure related to administration of i.v. contrast. Major toxicity (grade 3-4) included infection in 11% of patients, nausea/vomiting in 4%, diarrhea in 3%. Hematologic toxicity was mild to non-existent.We conclude that pentostatin is active in Sézary and MF but showed marginal activity in T-CLL or TZL. Toxicities are mild to moderate at the dose schedule administered. Due to its relatively specific lympholytic effect and its favorable toxicity spectrum, pentostatin might be especially useful for the palliative treatment of T-cell malignancies." @default.
• W2135087888 created "2016-06-24" @default.
• W2135087888 creator A5022642999 @default.
• W2135087888 creator A5035003166 @default.
• W2135087888 creator A5039285562 @default.
• W2135087888 creator A5053911589 @default.
• W2135087888 creator A5055745584 @default.
• W2135087888 creator A5059878458 @default.
• W2135087888 creator A5075669839 @default.
• W2135087888 creator A5078885918 @default.
• W2135087888 creator A5079852624 @default.
• W2135087888 creator A5086903284 @default.
• W2135087888 creator A5089395073 @default.
• W2135087888 date "1999-12-01" @default.
• W2135087888 modified "2023-09-26" @default.
• W2135087888 title "Pentostatin in T-cell malignancies – a phase II trial of the EORTC" @default.
• W2135087888 cites W1506762754 @default.
• W2135087888 cites W1517291270 @default.
• W2135087888 cites W1518533450 @default.
• W2135087888 cites W1797125879 @default.
• W2135087888 cites W1839751882 @default.
• W2135087888 cites W1880480935 @default.
• W2135087888 cites W1906398149 @default.
• W2135087888 cites W1910475489 @default.
• W2135087888 cites W1959866484 @default.
• W2135087888 cites W1965572371 @default.
• W2135087888 cites W1970321630 @default.
• W2135087888 cites W1993845235 @default.
• W2135087888 cites W1994380958 @default.
• W2135087888 cites W1998483083 @default.
• W2135087888 cites W1999516176 @default.
• W2135087888 cites W2000342145 @default.
• W2135087888 cites W2007938901 @default.
• W2135087888 cites W2008942922 @default.
• W2135087888 cites W2009870283 @default.
• W2135087888 cites W2025697028 @default.
• W2135087888 cites W2034519153 @default.
• W2135087888 cites W2052677652 @default.
• W2135087888 cites W2057685381 @default.
• W2135087888 cites W2078842009 @default.
• W2135087888 cites W2084899812 @default.
• W2135087888 cites W2089153420 @default.
• W2135087888 cites W2097778142 @default.
• W2135087888 cites W2111171221 @default.
• W2135087888 cites W2154495833 @default.
• W2135087888 cites W2244683952 @default.
• W2135087888 cites W2267793562 @default.
• W2135087888 cites W2325115734 @default.
• W2135087888 cites W2418823632 @default.
• W2135087888 cites W2474959262 @default.
• W2135087888 cites W263009922 @default.
• W2135087888 cites W3107692169 @default.
• W2135087888 cites W331981820 @default.
• W2135087888 cites W4236768471 @default.
• W2135087888 cites W4241791800 @default.
• W2135087888 doi "https://doi.org/10.1023/a:1008377724139" @default.
• W2135087888 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10643542" @default.
• W2135087888 hasPublicationYear "1999" @default.
• W2135087888 type Work @default.
• W2135087888 sameAs 2135087888 @default.
• W2135087888 citedByCount "41" @default.
• W2135087888 countsByYear W21350878882012 @default.
• W2135087888 countsByYear W21350878882013 @default.
• W2135087888 countsByYear W21350878882014 @default.
• W2135087888 countsByYear W21350878882015 @default.
• W2135087888 countsByYear W21350878882017 @default.
• W2135087888 countsByYear W21350878882020 @default.
• W2135087888 countsByYear W21350878882021 @default.
• W2135087888 crossrefType "journal-article" @default.
• W2135087888 hasAuthorship W2135087888A5022642999 @default.
• W2135087888 hasAuthorship W2135087888A5035003166 @default.
• W2135087888 hasAuthorship W2135087888A5039285562 @default.
• W2135087888 hasAuthorship W2135087888A5053911589 @default.
• W2135087888 hasAuthorship W2135087888A5055745584 @default.
• W2135087888 hasAuthorship W2135087888A5059878458 @default.
• W2135087888 hasAuthorship W2135087888A5075669839 @default.
• W2135087888 hasAuthorship W2135087888A5078885918 @default.
• W2135087888 hasAuthorship W2135087888A5079852624 @default.
• W2135087888 hasAuthorship W2135087888A5086903284 @default.
• W2135087888 hasAuthorship W2135087888A5089395073 @default.
• W2135087888 hasBestOaLocation W21350878881 @default.
• W2135087888 hasConcept C126322002 @default.
• W2135087888 hasConcept C141071460 @default.
• W2135087888 hasConcept C2775952470 @default.
• W2135087888 hasConcept C2776694085 @default.
• W2135087888 hasConcept C2777063308 @default.
• W2135087888 hasConcept C2777756187 @default.
• W2135087888 hasConcept C2778822529 @default.
• W2135087888 hasConcept C2779338263 @default.
• W2135087888 hasConcept C2780653079 @default.
• W2135087888 hasConcept C29730261 @default.
• W2135087888 hasConcept C71924100 @default.
• W2135087888 hasConcept C90924648 @default.
• W2135087888 hasConceptScore W2135087888C126322002 @default.
• W2135087888 hasConceptScore W2135087888C141071460 @default.
• W2135087888 hasConceptScore W2135087888C2775952470 @default.
• W2135087888 hasConceptScore W2135087888C2776694085 @default.
• W2135087888 hasConceptScore W2135087888C2777063308 @default.

• next